Not Yet RecruitingPhase 2

Tislelizumab Combined With Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma Followed by CRT or Surgery

60 participantsStarted 2025-08-01

Plain-language summary

To explore the non-inferiority of the 2y-OS rate of tislelizumab combined with chemotherapy after sequential CRT in the treatment of resectable esophageal squamous cell carcinoma compared with the surgical group

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Blood routine (no blood transfusion was performed within 14 days before treatment, no granulocyte colony-stimulating factor \[G-CSF\] was used, and no other drugs were used for correction);
✓. Blood biochemistry

What they're measuring

Overall survival rate of 2 years

Timeframe: 2 years

Trial details

NCT IDNCT07046221

SponsorFujian Cancer Hospital

Sponsor typeOTHER_GOV

Study typeINTERVENTIONAL

Primary completion2027-08-01

Contact for this trial

Chen jun qiang, bachelor

13705036281 junqiangc@163.com

View on ClinicalTrials.gov More Esophagus Cancer trials